STAT3 and neoplasm: Previous studies have shown that the IL-6-JAK-STAT3 signaling pathway is abnormally over-activated in patients with hematopoietic malignancies or solid tumors, to encourage tumor cell proliferation, survival, invasion, and metastasis (41).